Stock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data

Stock Track04-27 13:03

AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.

The sharp rise appears driven by continued positive investor sentiment following the release of encouraging clinical trial data. Recently at the AACR Annual Meeting, the company presented results from the COMPASSION-26 Phase II trial evaluating its PD-1/CTLA-4 bispecific antibody cadonilimab in combination with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma.

The data demonstrated robust anti-tumor activity with median overall survival reaching 23.4 months and median progression-free survival of 11.1 months in patients with locally advanced unresectable disease, representing meaningful improvement in a difficult-to-treat cancer indication.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125463972?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 13:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125463972","market":"us","top_or_hot":-1,"title":"Stock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data","media":"Stock Track","content":"<p>AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.</p><p>The sharp rise appears driven by continued positive investor sentiment following the release of encouraging clinical trial data. Recently at the AACR Annual Meeting, the company presented results from the COMPASSION-26 Phase II trial evaluating its PD-1/CTLA-4 bispecific antibody cadonilimab in combination with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma.</p><p>The data demonstrated robust anti-tumor activity with median overall survival reaching 23.4 months and median progression-free survival of 11.1 months in patients with locally advanced unresectable disease, representing meaningful improvement in a difficult-to-treat cancer indication.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AKESO Soars 5.24% Intraday on Positive Phase II Pancreatic Cancer Trial Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-27 13:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.</p><p>The sharp rise appears driven by continued positive investor sentiment following the release of encouraging clinical trial data. Recently at the AACR Annual Meeting, the company presented results from the COMPASSION-26 Phase II trial evaluating its PD-1/CTLA-4 bispecific antibody cadonilimab in combination with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma.</p><p>The data demonstrated robust anti-tumor activity with median overall survival reaching 23.4 months and median progression-free survival of 11.1 months in patients with locally advanced unresectable disease, representing meaningful improvement in a difficult-to-treat cancer indication.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1125463972","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125463972","pubTimestamp":1777266211,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.The sharp rise appears driven by continued positive investor...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"个股追踪|康方生物盘中大涨5.24%胰腺癌II期试验数据积极","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"AKESO's stock surged 5.24% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.The sharp rise appears driven by continued positive investor sentiment following the release of encouraging clinical trial data. Recently at the AACR Annual Meeting, the company presented results from the COMPASSION-26 Phase II trial evaluating its PD-1/CTLA-4 bispecific antibody cadonilimab in combination with chemotherapy as a first-line treatment for advanced pancreatic ductal adenocarcinoma.The data demonstrated robust anti-tumor activity with median overall survival reaching 23.4 months and median progression-free survival of 11.1 months in patients with locally advanced unresectable disease, representing meaningful improvement in a difficult-to-treat cancer indication.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125463972","isCrawlerRequest":true}